{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:53:38Z","timestamp":1790146418918,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2018.02.003","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T17:49:59Z","timestamp":1518457799000},"page":"S71-S82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":189,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Mikulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Drgona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Salzberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.02.003_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.02.003_bib2","first-page":"76","article-title":"Advancements in therapy for acute lymphoblastic leukemia: blinatumomab","volume":"7","author":"Hladnik","year":"2016","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.2011.08762.x","article-title":"A\u00a0phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia","volume":"154","author":"Schindler","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.003_bib4","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.003_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.003_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2018.02.003_bib8","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib9","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.02.003_bib10","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.003_bib12","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","author":"Agius","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.cmi.2018.02.003_bib13","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1182\/blood.V124.21.4472.4472","article-title":"Results of a phase 2 study of MEDI-551 and bendamustine vs rituximab and bendamustine in relapsed or refractory chronic lymphocytic leukemia","volume":"124","author":"Gladstone","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.003_bib14","first-page":"1302","article-title":"A\u00a0phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19+, CD22+ B cell lymphoma","volume":"6","author":"Messmann","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2018.02.003_bib15","first-page":"347","article-title":"Development of novel anti-CD20 monoclonal antibodies and modulation in CD20 levels on cell surface: looking to improve immunotherapy response","volume":"7","author":"Singh","year":"2015","journal-title":"J\u00a0Cancer Sci Ther"},{"key":"10.1016\/j.cmi.2018.02.003_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.003_bib17","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.003_bib18","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B\u00a0cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.003_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.003_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000377","article-title":"Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy","volume":"29","author":"Kado","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.003_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"Qjm"},{"key":"10.1016\/j.cmi.2018.02.003_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nri2729","article-title":"Effector and regulatory B cells: modulators of CD4+ T cell immunity","volume":"10","author":"Lund","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2018.02.003_bib23","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-13-317","article-title":"Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study","volume":"13","author":"Lanini","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib25","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","article-title":"Neurological sequelae of cancer immunotherapies and targeted therapies","volume":"17","author":"Wick","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428191003699860","article-title":"High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone","volume":"51","author":"Kamel","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.02.003_bib27","doi-asserted-by":"crossref","first-page":"945950","DOI":"10.1155\/2012\/945950","article-title":"Rituximab-based treatment, HCV replication, and hepatic flares","volume":"2012","author":"Sagnelli","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cmi.2018.02.003_bib28","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/14397595.2014.948981","article-title":"Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis","volume":"27","author":"Tsuji","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"19","key":"10.1016\/j.cmi.2018.02.003_bib30","first-page":"1345","article-title":"Fatal case of enterovirus 71 infection and rituximab therapy, France","volume":"2013","author":"Kassab","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib31","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3201\/eid2109.150104","article-title":"Disseminated enteroviral infection associated with obinutuzumab","volume":"21","author":"Dendle","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"10.1016\/j.cmi.2018.02.003_bib32","first-page":"913","article-title":"Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium","volume":"2014","author":"Eyckmans","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.4049\/jimmunol.1302661","article-title":"B\u00a0cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection","volume":"192","author":"Misumi","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.02.003_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.02.003_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.cmi.2018.02.003_bib36","first-page":"684","article-title":"Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma","volume":"22","author":"Emmanouilides","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.cmi.2018.02.003_bib37","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.3324\/haematol.2015.132035","article-title":"A\u00a0phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients","volume":"100","author":"Tedeschi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.003_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2016.152272","article-title":"Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma","volume":"102","author":"Grigg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.003_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cmi.2018.02.003_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.cmi.2018.02.003_bib41","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14760584.2016.1193438","article-title":"Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients","volume":"15","author":"Cheng","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2018.02.003_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jth.13622","article-title":"Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect","volume":"15","author":"Moulis","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cmi.2018.02.003_bib43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host","volume":"96","author":"de Lavallade","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.003_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib45","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.003_bib46","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib47","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cmi.2018.02.003_bib48","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3324\/haematol.2009.005819","article-title":"Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance","volume":"94","author":"Ziakas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.003_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ajt.12649","article-title":"Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation","volume":"14","author":"Martin","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.003_bib50","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmi.2017.06.024","article-title":"Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review","volume":"23","author":"Gentile","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.02.003_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","article-title":"Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper","volume":"23","author":"Sarmati","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.02.003_bib52","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver (EASL) 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2018.02.003_bib54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.dld.2010.05.010","article-title":"HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens","volume":"43","author":"Marignani","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib55","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/rheumatology\/kew282","article-title":"Chronic hepatitis E in a patient treated with rituximab and mycophenolate mofetil for Sj\u00f6gren's syndrome","volume":"55","author":"Fraticelli","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2018.02.003_bib56","doi-asserted-by":"crossref","first-page":"e0122171","DOI":"10.1371\/journal.pone.0122171","article-title":"Prophylaxis and treatment of Pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.003_bib57","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24499","article-title":"Low incidence of Pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy","volume":"91","author":"Barreto","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2018.02.003_bib58","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2018.02.003_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-016-0207-0","article-title":"Biosimilars for the treatment of cancer: a systematic review of published evidence","volume":"31","author":"Jacobs","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.cmi.2018.02.003_bib60","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib61","first-page":"370","article-title":"Obinutuzumab: a novel anti-CD20 monoclonal antibody for chronic lymphocytic leukemia","volume":"6","author":"Evans","year":"2015","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib62","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib63","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon-\u03b21a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087379","article-title":"Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program","volume":"9","author":"Emery","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.003_bib67","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.003_bib68","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.003_bib69","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B virus screening for patients with cancer before therapy: American society of clinical oncology provisional clinical opinion update","volume":"33","author":"Hwang","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.003_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib71","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cmi.2018.02.003_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008078.pub2","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2018.02.003_bib73","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib74","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial","volume":"384","author":"Haynes","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.003_bib75","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon-\u03b21a as first-line treatment for patients with relapsing\u2013remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.003_bib76","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon \u03b2-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.003_bib77","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease modifying therapy a randomised-controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.003_bib78","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1086\/375690","article-title":"Tuberculosis due to Mycobacterium bovis after alemtuzumab administration","volume":"37","author":"Abad","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.003_bib79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ajh.20780","article-title":"Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab","volume":"82","author":"Cheung","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2018.02.003_bib80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000189713.14993.db","article-title":"Campath-1H induction and the incidence of infectious complications in adult renal transplantation","volume":"81","author":"Malek","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.003_bib81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:11:32Z","timestamp":1668762692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18301514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":81,"alternative-id":["S1198743X18301514"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.02.003","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}